Clinicians Are Invited to View a Multidisciplinary, Online Panel Discussion on Evolving Treatment Strategies for HER2-Positive Breast Cancer

BALTIMORE, MD—March 19, 2015 —As neoadjuvant therapy becomes the standard treatment approach for locally advanced HER2-positive breast cancer, medical and surgical oncologists have new agents and regimens available to them.

Med-IQ, an ACCME-accredited provider of continuing medical education (CME), has released the free Webcast, Contemporary Strategies in the Treatment of HER2-Positive Breast Cancer: A Multidisciplinary, Case-Based Approach, which uses a discussion-based format and real-life patient scenarios to explore the clinical implications of these new therapies.

Medical oncologist Adam M. Brufsky, MD, PhD, and surgical oncologist Monica Morrow, MD, offer expert perspectives regarding the outcomes associated with HER2-directed neoadjuvant therapy. They also provide guidance on developing treatment strategies based on patient receptor status and managing treatment-related side effects.

“The treatment landscape in locally advanced breast cancer is shifting away from traditional chemotherapy approaches to more individualized regimens,” says Dr. Brufsky, Associate Chief of Hematology-Oncology at the University of Pittsburgh Cancer Institute. “This Webcast provides medical and surgical oncologists with new approaches to begin assimilating these therapies into routine practice.”

FACULTY

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief of Hematology-Oncology
Associate Director of Clinical Investigation
University of Pittsburgh Cancer Institute
Pittsburgh, PA

Monica Morrow, MD
Chief, Breast Surgical Service
Anne Burnett Windfohr Chair of Clinical Oncology
Memorial Sloan Kettering Cancer Center
Professor of Surgery, Weill Cornell Medical College
New York, NY

Clinicians are invited to visit www.Med-IQ.com/a783 for complimentary access to this educational opportunity. For more information, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

This activity is approved for AMA PRA Category 1 Credit™ and supported by an educational grant from Genentech.

About Med-IQ

Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.

As a leader in the CME industry, Med-IQ has delivered 32 performance improvement (PI) and quality improvement (QI) initiatives that make use of systems-based training such as Crew Resource Management (CRM) to improve team performance and patient outcomes. These initiatives have achieved improvement in healthcare professional performance, quality of care, and patient outcomes. Med-IQ's work in this space has been published 30 times in peer-reviewed journals, and the company has been recognized by the Alliance for Continuing Education in the Health Professions for excellence in CEhp research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership and contributions to the CEhp profession (Leadership Award 2015, 2013; Distinguished Fellow Award 2015; President’s Award 2015, 2012; Rising Star Award 2015). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.

For more information, contact:

Amy Caswell
Senior Audience Development Manager
Med-IQ
866 858 7434
info@med-iq.com


Med-IQ.
Inspiring Medical Education.